influenza a virus (iav)

CEF8, Influenza Virus NP (383-391), is an influenza A virus nucleoprotein containing residues 383 to 391, and it is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses, associated with escape from cytotoxic T lymphocytes-mediated immunity. [HLA-B*3501 restricted influenza virus nucleoprotein epitope (383-391).]

Influenza A virus-IN-8 (S5), a macrocyclic peptide, exhibits no cytotoxicity and acts as a potent inhibitor of Influenza A Virus (IAV), demonstrating significant protease stability, with IC50 values of 6.7 nM for H1 and 6.6 nM for H5 variants. It has a high affinity for H1 variants, binding to a conserved region in the HA stem with a dissociation constant (Kd) of 1.0 nM [1].

Partial antigenic glycoprotein

HLA-B*08 restricted influenza virus nucleoprotein epitope.

Defensin HNP-3 is a peptide secreted by human polymorphonuclear leukocytes (PMNs) that has antimicrobial properties. It induces lysis of mammalian cells when used at a concentration of 25 μg/mL. It also inhibits growth of E. faecalis (ED50 = 100 nM) and clinical isolates of P. aeruginosa (MIC90 = 4 μM). HNP-3 binds to recombinant HIV-1 envelope glycoprotein (gp120) and human CD4 (Kds = 52.8 and 34.9 nM, respectively). It also binds to recombinant, immobilized human surfactant protein D (SP-D; Kd = 55.7 nM) and inhibits focus formation in Madin-Darby canine kidney (MDCK) cells infected with influenza A virus (IAV).

Z-VRPR-FMK (TFA), a selective and irreversible inhibitor of Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), is a tetrapeptide shown to provide protection against influenza A virus (IAV) infection [1].